Certara, Inc. (NASDAQ:CERT) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Certara, Inc. has received an average rating of "Moderate Buy" from ten brokerages, with five analysts recommending a buy and five a hold.
• The company's average 12-month price target from analysts is $15.14, with notable adjustments from firms such as KeyCorp and UBS Group lowering their targets.
• Insider Leif E. Pedersen recently sold 51,224 shares valued at approximately $559,366, representing a 40.91% decrease in their ownership stake.

Certara, Inc. (NASDAQ:CERT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $15.1429.

CERT has been the subject of several research analyst reports. Morgan Stanley initiated coverage on Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. KeyCorp reduced their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. UBS Group reduced their price objective on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, Zacks Research raised Certara from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th.

Insider Transactions at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider directly owned 73,979 shares of the company's stock, valued at approximately $807,850.68. This represents a 40.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.33% of the company's stock.

Institutional Investors Weigh In On Certara

Hedge funds and other institutional investors have recently made changes to their positions in the company. AdvisorNet Financial Inc purchased a new stake in shares of Certara during the 2nd quarter worth about $25,000. Versant Capital Management Inc raised its stake in shares of Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Certara during the 1st quarter worth about $31,000. AlphaQuest LLC purchased a new stake in shares of Certara during the 1st quarter worth about $39,000. Finally, Osaic Holdings Inc. raised its stake in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock worth $41,000 after purchasing an additional 1,175 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Trading Up 3.3%

Shares of NASDAQ CERT opened at $11.28 on Monday. Certara has a 12 month low of $8.64 and a 12 month high of $15.69. The company has a market cap of $1.81 billion, a price-to-earnings ratio of 225.65 and a beta of 1.43. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The business has a fifty day simple moving average of $10.73 and a 200-day simple moving average of $11.27.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The company had revenue of $104.57 million for the quarter, compared to analysts' expectations of $104.14 million. During the same period in the prior year, the company earned $0.07 earnings per share. The company's revenue for the quarter was up 12.1% on a year-over-year basis. Sell-side analysts predict that Certara will post 0.28 EPS for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.